Fate Therapeutics (FATE) Stock Analysis & AI Equity Report
Fate Therapeutics (FATE) overview
Fate Therapeutics (FATE) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 6.6m and operating profit of USD -148m; the year-end share price was 0.98 USD and market capitalisation was USD 113m. Fate Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Fate Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Fate Therapeutics
Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies for cancer and autoimmune diseases. Using a proprietary induced pluripotent stem cell platform, it engineers clonal master cell lines and differentiates them into uniform T-cell and natural killer cell candidates. Its pipeline includes chimeric antigen receptor-targeted therapies designed for potential use alone or alongside standard treatments.
Generate the Fate Therapeutics report
Fate Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Fate Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Fate Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.